(Reuters) - Bristol-Myers Squibb Co said the independent data monitoring committee concluded that a late stage study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment